Canada: a haven for generic drugs?
Medical News Today reports that Canada is proposing to amend its patent law in order to optimize the balance between encouraging continued innovation in new drugs and promoting timely generic competition. Under the proposal pharmaceutical companies will not be able to extend the period of data exclusivity that they are granted in a way that is incompatible with the original purpose of such protection. This should enable generics to come to the market more easily. However, for genuinely innovative drugs, the data exclusivity period will be extended from 6 years to 8 years, with an extra 6 months for drugs which have been the subject of clinical trials on children.
The IPKat welcomes this subtle approach, which directs its measures specifically to the problems identified, rather than a “one size fits all” approach.
More on generic drugs in Canada here, here and here
Canada-related Monty Python sketch here